SciVision Biotech

What SciVision Biotech does

SciVision Biotech is a Taiwan-listed specialty biotechnology company (TWSE: 1786) founded in 2001 and headquartered in Kaohsiung, Taiwan. The company produces medical-grade hyaluronic acid (HA) using fermentation biotechnology, serving medical device, pharmaceutical, and aesthetic/cosmetic end-markets that consume HA as a key raw material or active ingredient.

The company's core offering is fermentation-derived medical HA, leveraging proprietary bioprocess know-how accumulated over more than two decades of operation. Fermentation-based HA production is the central technology platform and the basis of SciVision's competitive position versus animal-tissue extraction alternatives. The company operates with a small employee base (51-100 per firmographics), suggesting a focused, capital-efficient manufacturing model concentrated on a specialty chemistry process rather than broad-based discovery R&D. Specific product grades, packaging formats, certifications, and customer applications are not disclosed in available sources.

SciVision's commercial model operates as a B2B upstream supplier into the medical HA value chain. Pricing models, customer segment mix, distribution channels, and revenue mechanics are not publicly disclosed in the available data. Reported financials show multi-year revenue expansion from FY2021 through FY2025 with EBITDA and net income also expanding through FY2024, before a FY2025 net income decline that warrants attention. The financial figures carry apparent unit ambiguity (column header indicates USD millions while values resemble New Taiwan Dollar denominations); the directional trend is nonetheless consistent with sustained commercial growth, peaking profitability in FY2024, and margin pressure emerging in FY2025.

Name

SciVision Biotech

Website

https://scivision.com.tw

Company type

Private

Founded year

2001

Headcount range

11–50 employees

Short description

SciVision Biotech (TWSE: 1786) is a Taiwan-listed, Kaohsiung-based fermentation biotechnology company founded in 2001 that produces medical-grade hyaluronic acid for medical device, pharmaceutical, and cosmetic customers, operating with a focused specialty manufacturing model.

Ownership category

akta.pro rank

Product category

Medical Hyaluronic Acid Manufacturing

NAICS

Biological Product (except Diagnostic) Manufacturing (325414)

SIC

Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Wound Healing & Skin Regeneration (advanced dressings, skin substitutes) (HLAAAGAG)

Keywords

• Hyaluronic acid production
• Fermentation biotechnology
• Medical biomaterials
• Dermal filler materials
• Ophthalmic viscoelastic devices

Headquarters

HQ city

Kaohsiung

HQ country

Taiwan

HQ region

Asia

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Operations, Supply Chain, Technology or R&D, Marketing or Sales

Core offering

SciVision Biotech manufactures medical-grade hyaluronic acid (HA) using proprietary fermentation biotechnology. The company produces HA-based biomaterials supplied to medical device and pharmaceutical customers for use in dermal fillers, intra-articular injections for osteoarthritis, ophthalmic viscosurgical devices, and other clinical applications.

Differentiator

Problem solved

Functional benefit

Products and services

• Medical-grade hyaluronic acid (HA) raw material Fermentation-derived medical-grade hyaluronic acid supplied as a raw biomaterial to medical device and pharmaceutical manufacturers for incorporation into finished clinical products including dermal fillers, intra-articular injections for joint conditions, and ophthalmic viscosurgical devices.

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Recent moves3 records

Expansion highlights3 records

Direct peers

• Shandong Topscience Biotech: Topscience is a Chinese producer of medical-grade HA and related injectables, comparable as a regional fermentation HA manufacturer.
• Anika Therapeutics: Anika markets Orthovisc and Monovisc, HA-based intra-articular injections for osteoarthritis, overlapping directly with SciVision's medical HA end-uses.
• Shanghai Haohai Biological Technology: Haohai is a publicly-traded Chinese biotech producing HA-based orthopedic and ophthalmic products — directly comparable medical HA competitor in Asia.
• Ferring Pharmaceuticals: Ferring produces medical HA products for reproductive medicine and orthopedics, comparable to SciVision in indication and product format.
• Bloomage Biotech: Bloomage is the world's largest producer of fermentation-grade hyaluronic acid for medical, cosmetic, and skincare uses — directly comparable to SciVision's medical HA fermentation platform.
• LG Chem Life Sciences: Korea-based LG Chem produces Hyruan-series medical HA viscosupplements and ophthalmic products, making it a direct competitor in medical-grade HA.
• Seikagaku Corporation: Seikagaku develops and manufactures HA-based products including ARTZ/SUPARTZ for joint disorders — closely comparable in product type and therapeutic focus.

Broad incumbents

• Galderma: Galderma offers HA-based aesthetics and dermatology products (e.g., Restylane portfolio via Nestlé Skin Health history), overlapping with cosmetic/medical HA end-uses.
• AbbVie (Allergan Aesthetics): Allergan/AbbVie sells HA-based dermal fillers (Juvéderm) alongside a broad aesthetics portfolio — an adjacent incumbent in injectable HA categories.
• Sanofi (Genzyme): Sanofi markets Synvisc-One (hylan G-F 20, HA-based viscosupplementation), overlapping SciVision's orthopedic HA end-uses within a much larger diversified pharma portfolio.

Market position

Strengths3 records

Weaknesses3 records

Competitive moat3 records

Key risks3 records

Key highlights3 records

Customer concentration

• LinkedInlinkedin.com/company/scivision-biotech-inc

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about SciVision Biotech